Sorrento Therapeutics (SRNE +9.1%) has agreed to co-develop an antibody cocktail called COVI-SHIELD for the potential treatment of COVID-19 with Mount Sinai Health System.
COVI-SHIELD will consist of antibodies identified
in plasma of ~15K patients who have recovered from the respiratory
infection that was screened with a Mt. Sinai-developed test. Three
antibodies will be used that bind to three unique regions of the
SARS-CoV-2 spike protein, thereby interfering with its ability to infect
healthy cells.
The company says the therapy is designed to be
administered as often as necessary and to provide antiviral protection
for up to two months.
https://seekingalpha.com/news/3572225-sorrento-teams-up-mount-sinai-to-develop-covidminus-19-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.